Acute myelomonocytic leukemia during pembrolizumab treatment for non-small cell lung cancer: A case report

作     者：Hong-Beum Kim Sang-Gon Park Ran Hong Seong-Ho Kang Yong Sub Na 

作者机构：Department of Premedical CourseChosun University School of MedicineGwangju 61452South Korea Department of Hemato-oncologyChosun University HospitalGwangju 61453South Korea Department of PathologyChosun University HospitalGwangju 61453South Korea Department of Laboratory MedicineChosun University HospitalGwangju 61453South Korea Department of Pulmonology and Critical Care MedicineChosun University HospitalGwangju 61453South Korea 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2020年第8卷第13期

页      面：2833-2840页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by the National Research Foundation of Korea funded by the Ministry of Science ICT and Future Planning No.NRF-2015R1A5A2009070 

主　　题：Acute myeloid leukemia Immunotherapy Non-small cell lung cancer Adverse events Case report 

摘      要：BACKGROUND Pembrolizumab is a highly selective IgG4 kappa isotype monoclonal antibody against the programmed cell death-1(PD-1)*** the treatment of nonsmall cell lung cancer(NSCLC),pembrolizumab has demonstrated significant efficacy,significant survival outcomes,long-lasting responses,and a good safety profile compared with cytotoxic *** SUMMARY A 79-year-old Korean male presented with a left side palpable neck *** ultrasound-guided core-needle biopsy of the largest neck mass was performed,and squamous cell carcinoma was confirmed based on the histological and immunohistochemical *** was diagnosed with squamous cell carcinoma of the lung with multiple lymph nodes and rib metastases(T1N3M1b,Stage IVA)using enhanced chest computed tomography and 18F-fluorodeoxyglucose positron emission/computed *** 4 cycles of gemcitabine and carboplatin,we clinically judged the disease as *** to the high PD-1 expression demonstrated by the patient,pembrolizumab was initiated(200 mg every 3 wk).After 3 cycles of pembrolizumab,a complete response was *** the 4th cycle of pembrolizumab,the white blood cell count was markedly *** blood smear analysis and bone marrow biopsy were *** patient was diagnosed with acute myelomonocytic *** We present the first report of acute myelomonocytic leukemia during pembrolizumab treatment in an NSCLC patient;the mechanism remains unknown.